Global Neoantigen Peptides Manufacturing Market Size is valued at USD 1.4 Billion in 2024 and is predicted to reach USD 6.3 Billion by the year 2034 at a 16.4% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Neoantigens are newly generated peptides that are capable of inducing tumour-specific T cell recognition. These are created through somatic mutations. Researchers and physicians have recently used next-generation sequencing technology to detect neoantigens and develop tailored cancer immunotherapies. Neoantigens are short peptides derived from tumour-specific somatic mutations. These peptides bind to HLA (Human Leucocyte Antigen) molecule to be recognized by T-Cell Receptors (TCRs), which further activate the immune system for specific cancer cells. In manufacturing neoantigen-based vaccines, personalized neoantigen peptides are synthesized, which helps induce the T-cell population. This new type of immunotherapy can produce a strong and specific immune response and draw out stable therapeutic effects. As a result, personalized neoantigen peptide vaccines are designed to train a patient's immune system to target and kill tumour cells. Hence they are used to develop vaccines and immunotherapies against cancer cells. These significant neoantigens can control tumour outgrowth and felicitate cellular transformation.
Synthetic peptides are a recognized model of cancer vaccine delivery, but creating the peptides for each patient rapidly and inexpensively remains difficult. The rising number of clinical trials, the growth in cancer and chronic illness cases, and the necessity for long-term therapy for these diseases are all prominent market factors for Neoantigen peptide synthesis. Furthermore, advances in biotechnology research will help researchers better understand individualized neoantigen peptides. Increased external investment in cancer drug research and development, on the other hand, drives the market upward. On the other hand, costly designing and development of personalized cancer therapeutics and delayed clinical trials due to the COVID-19 impact will restrain the market.
The Neoantigen Peptides Manufacturing Market is segmented into the Scale of operations, end-users, and region. The scope of operation segment comprises research/preclinical, clinical, and commercial. The market is segmented into pharmaceutical/vaccine developer companies, contract research organizations (CRO), and academic & research institutes by end-users. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The North American market can witness rapid growth during the forecast period (2020-2030) due to the well-established healthcare infrastructure, growing research regarding Peptide synthesis, and the rising government efforts to develop personalized vaccines.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 1.4 Billion |
|
Revenue Forecast In 2034 |
USD 6.3 Billion |
|
Growth Rate CAGR |
CAGR of 16.4% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn,, Volume (Unit), and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Scale of Operations, by End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; Souh Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
CPC Scientific Inc, Polypeptide group, Genscript Biotech, Kaneka Eurogentec S.A., Vivitide, Almac, BCN Peptides, Creative Peptides, Pepscan, Provepharm, Creosalus, AnaSpec, Gyros Protein Technologies, Other Prominent Players |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neoantigen Peptides Manufacturing Market Snapshot
Chapter 4. Global Neoantigen Peptides Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Investment and Funding Analysis for Neoantigen Vaccine and Therapeutic Development
4.7. Clinical Trial/Pipeline Analysis for Neoantigen Cancer Vaccine
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Scale of Operations Estimates & Trend Analysis
5.1. By Scale of Operations & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Scale of Operations:
5.2.1. Research / Preclinical
5.2.2. Clinical
5.2.3. Commercial
Chapter 6. Market Segmentation 2: By End-Users Estimates & Trend Analysis
6.1. By End-Users & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Users:
6.2.1. Pharmaceutical/Vaccine Developers Companies
6.2.2. Contract Research Organization (CRO)
6.2.3. Academic and Research Institutes
Chapter 7. Neoantigen Peptides Manufacturing Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operations, 2021-2034
7.1.2. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts By Therapy, 2021-2034
7.1.3. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.1.4. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.2.2. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
7.2.3. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.2.4. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.3.2. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
7.3.3. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.3.4. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.4.2. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
7.4.3. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.4.4. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.5.2. Middle East & Africa Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. CPC Scientific Inc
8.2.2. Polypeptide group
8.2.3. Genscript Biotech
8.2.4. Kaneka Eurogentec S.A.
8.2.5. Vivitide
8.2.6. Almac
8.2.7. BCN Peptides
8.2.8. Creative Peptides
8.2.9. Pepscan
8.2.10. Provepharm
8.2.11. Creosalus
8.2.12. Gyros Protein Technologies
8.2.13.AnaSpec
8.2.14. Other Prominent Players
Global Neoantigen Peptides Manufacturing Market, by Scale of operations, 2020-2030 (Value US$ Mn)
Global Neoantigen Peptides Manufacturing Market, by End-Users 2020-2030 (Value US$ Mn)
Global Neoantigen Peptides Manufacturing Market, by Region, 2020-2030 (Value US$ Mn)
North America Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
Europe Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
Asia Pacific Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
Latin America Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
Middle East & Africa Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
Rest of Middle East & Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
